What Icatibant is
Icatibant is a bradykinin B2 receptor antagonist peptide medicine used in approved angioedema contexts.
Icatibant is grouped under Approved / Clinical on PeptideFactCheck because it is a good example of a peptide antagonist built around a very specific physiology problem.
The useful starting point is to separate the molecule itself from the internet story around it. It is a good example of a peptide antagonist built around a very specific physiology problem.
Why people keep looking it up
It is a good example of a peptide antagonist built around a very specific physiology problem.
Icatibant is a bradykinin B2 receptor antagonist peptide medicine used in approved angioedema contexts.
Icatibant tends to stay in the conversation because it touches a familiar public theme: bradykinin b2 receptor, angioedema, and peptide antagonist. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved peptide antagonist with direct human and label support.
Human trials and official labeling support specific approved uses.
Mechanism follows bradykinin-receptor pharmacology and vascular-permeability biology.
Why this page carries the current tier: Approved peptide antagonist with direct human and label support.
The current seed trail for Icatibant is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Its clinical use is specific and should not be generalized into broad inflammation claims.
FDA-approved icatibant products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Icatibant. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Icatibant is CID 6918173. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 6918173
- Formula
- C59H89N19O13S
- Molecular weight
- 1304.5
- InChIKey
- QURWXBZNHXJZBE-SKXRKSCCSA-N
Matched synonyms include Icatibant, 130308-48-4, icatibanto, HOE140, 7PG89G35Q7, DTXSID20903963, L-Arginine, D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2alpha,3abeta,7abeta)-octahydro-1H-indole-2-carbonyl-, JE-049.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Icatibant returns 33 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Icatibant returns 1540 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- SAJAZIR
- Generic names
- ICATIBANT
- Routes
- SUBCUTANEOUS
- Application numbers
- ANDA212446
Indications and usage. 1 INDICATIONS AND USAGE SAJAZIR (icatibant) injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. SAJAZIR (icatibant) injection is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. ( 1 )
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Laryngeal attacks: Following treatment of laryngeal attacks with SAJAZIR, advise patients to seek immediate medical attention. ( 5.1 ) 5.1 Laryngeal Attacks Given the potential for airway obstruction during acute laryngeal HAE attacks, patients should be advised to seek medical attention in an appropriate healthcare facility immediately in addition to treatment with SAJAZIR.
Contraindications. 4 CONTRAINDICATIONS None. None. ( 4 )
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.